Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond

Teoh PJ. et al, (2025), Haematologica, 110, 1074 - 1091

ADAR1 in lenalidomide resistance: still immunomodulation?

Gooding S., (2025), Blood, 145, 1104 - 1106

Quantitative liver function imaging and whole genome sequencing - Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?

Welsh F. et al, (2025), Hpb (oxford)

Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.

TREATT Trial Investigators None., (2025), Lancet haematol, 12, e14 - e22

Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.

Van Oekelen O. et al, (2024), Cell rep med, 5

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Agarwal G. et al, (2024), Haematologica, 109, 1960 - 1965

Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.

Twumasi C. et al, (2024), Eur j haematol, 112, 547 - 553

High Success Rates Utilizing Local Standard of Care Cytogenetic Testing for Risk Stratified Frontline Therapy for Newly Diagnosed Multiple Myeloma: Experience from the Ukmra RADAR Study

Mehta D. et al, (2023), Blood, 142, 6715 - 6715

Data from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Data from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 1 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 1 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 2 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 2 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 3 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 3 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 4 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 4 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 5 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Supp Table 5 from Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies

Khan AO. et al, (2023)

Load More

Include forthcoming?